Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.

Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2023 03; 7:e2200483.

View in: PubMed

subject areas

High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Male
Prostatic Neoplasms, Castration-Resistant

authors with profiles

Akash Patnaik